Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
IL17A Blockade with Ixekizumab Suppresses MuvB Signaling in Clinical Psoriasis.
Ochsner SA, Pedroza M, Pillich RT, Krishnan V, Konicek BW, Dow ER, Park SY, Agarwal SK, McKenna NJ. Ochsner SA, et al. Among authors: konicek bw. J Invest Dermatol. 2023 Sep;143(9):1689-1699. doi: 10.1016/j.jid.2023.03.1658. Epub 2023 Mar 24. J Invest Dermatol. 2023. PMID: 36967086 Free article.
Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor).
Gooderham M, Vender R, Crowley J, Hong HC, Feely M, Garrelts A, See K, Konicek B, Green L. Gooderham M, et al. Dermatol Ther (Heidelb). 2024 Feb;14(2):441-451. doi: 10.1007/s13555-023-01075-y. Epub 2024 Feb 9. Dermatol Ther (Heidelb). 2024. PMID: 38332436 Free PMC article.
Baseline Characteristics and mNAPSI Change from Baseline Scores Through Month 12 for Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Nail Psoriasis Treated with Biologics from PSoHO.
Riedl E, Pinter A, Zaheri S, Costanzo A, Brnabic A, Konicek B, McKenzie R, Lampropoulou A, Rayes ME, Haustrup N, Schuster C. Riedl E, et al. Dermatol Ther (Heidelb). 2024 Apr 22. doi: 10.1007/s13555-024-01150-y. Online ahead of print. Dermatol Ther (Heidelb). 2024. PMID: 38649673
Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors.
Konicek BW, Capen AR, Credille KM, Ebert PJ, Falcon BL, Heady GL, Patel BKR, Peek VL, Stephens JR, Stewart JA, Stout SL, Timm DE, Um SL, Willard MD, Wulur IH, Zeng Y, Wang Y, Walgren RA, Betty Yan SC. Konicek BW, et al. Oncotarget. 2018 Feb 13;9(17):13796-13806. doi: 10.18632/oncotarget.24488. eCollection 2018 Mar 2. Oncotarget. 2018. PMID: 29568395 Free PMC article.
Pharmacogenetic inhibition of eIF4E-dependent Mmp9 mRNA translation reverses fragile X syndrome-like phenotypes.
Gkogkas CG, Khoutorsky A, Cao R, Jafarnejad SM, Prager-Khoutorsky M, Giannakas N, Kaminari A, Fragkouli A, Nader K, Price TJ, Konicek BW, Graff JR, Tzinia AK, Lacaille JC, Sonenberg N. Gkogkas CG, et al. Among authors: konicek bw. Cell Rep. 2014 Dec 11;9(5):1742-1755. doi: 10.1016/j.celrep.2014.10.064. Epub 2014 Nov 26. Cell Rep. 2014. PMID: 25466251 Free PMC article.
27 results